U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H19N3O5S.3H2O
Molecular Weight 419.4517
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of (2S,5R,6R)-6-((R)-(-)-2-AMINO-2-(P-HYDROXYPHENYL)ACETAMIDO)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCL(3.2.0)HEPTANE-2-CARBOXYLIC ACID TRIHYDRATE

SMILES

CC1(C)[C@]([H])(C(=O)O)N2C(=O)[C@]([H])([C@@]2([H])S1)N=C([C@@]([H])(c3ccc(cc3)O)N)O.O.O.O

InChI

InChIKey=MQXQVCLAUDMCEF-CWLIKTDRSA-N
InChI=1S/C16H19N3O5S.3H2O/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;;;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);3*1H2/t9-,10-,11+,14-;;;/m1.../s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H19N3O5S
Molecular Weight 365.4059
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Amoxicillin is one of the widely prescribed antibacterial agents, which was discovered by scientists at Beecham Research Laboratories in 1972. In the US GlaxoSmithKline markets it under the original brand name Amoxil. It is the first line treatment for middle ear infections. It is also used for strep throat, pneumonia, skin infections, and urinary tract infections it is taken by mouth. Amoxicillin inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs) that are located inside the bacterial cell wall. This results in a formation of defective cell wall and a cell death. Common side effects include nausea and rash. It may also increase the risk of yeast infections and, when used in combination with clavulanic acid, diarrhea. It should not be used in those who are allergic to penicillin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.8 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
37.6 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.5 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Disc. AE: Pharyngolaryngeal pain...
Other AEs: Nausea, Pharyngotonsillitis...
AEs leading to
discontinuation/dose reduction:
Pharyngolaryngeal pain (severe, 0.6%)
Other AEs:
Nausea (1.5%)
Pharyngotonsillitis (0.9%)
Vulvovaginal candidiasis (0.9%)
Headache (0.7%)
Diarrhea (0.5%)
Abdominal pain (0.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 0.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Diarrhea 0.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Headache 0.7%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Pharyngotonsillitis 0.9%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Vulvovaginal candidiasis 0.9%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Nausea 1.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Pharyngolaryngeal pain severe, 0.6%
Disc. AE
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
2001
Amoxicillin plus metronidazole in the treatment of adult periodontitis patients. A double-blind placebo-controlled study.
2001 Apr
Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy?
2001 Apr
Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics.
2001 Apr
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea.
2001 Apr
Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections.
2001 Apr
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
2001 Apr
Helicobacter eradication versus prompt endoscopy for dyspepsia.
2001 Apr
Simultaneous determination of five beta-lactam antibiotics in bovine milk using liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
2001 Apr 1
Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media.
2001 Apr 6
[Eradication therapy of Helicobacter pylori infection].
2001 Feb
[The history of Helicobacter pylori].
2001 Feb
Management of brain stem abscess.
2001 Feb
Cefprozil versus high-dose amoxicillin/clavulanate in children with acute otitis media.
2001 Feb
Differentiation between reinfection and recrudescence of helicobacter pylori strains using PCR-based restriction fragment length polymorphism analysis.
2001 Feb
The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins.
2001 Feb
Spectrophotometric determination of ampicillin, dicluxacillin, flucloxacillin and amoxicillin antibiotic drugs: ion-pair formation with molybdenum and thiocyanate.
2001 Feb
Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet.
2001 Feb
Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic.
2001 Feb
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
2001 Feb
[Prevention of bacterial endocarditis in patients with prosthetic heart valves].
2001 Feb 15
Clostridium difficile--Associated diarrhea: A review.
2001 Feb 26
Improved phagocyte response by co-amoxiclav in renal transplant recipients.
2001 Feb 27
Definite streptococcus bovis endocarditis: characteristics in 20 patients.
2001 Jan
[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].
2001 Jan
[Prevalence and treatment of Helicobacter pylori in gastro-duodenal ulcers. An experience in Liege].
2001 Jan
Antibiotic susceptibilities of Helicobacter pylori.
2001 Jan
[Pneumococcal antibiotic resistance. Results from 21 regional registries for 1999].
2001 Jan
[Pneumococcal antibiotic resistance in 1999. Results from 19 registries for 1999].
2001 Jan
[Pneumococcal antibiotic resistance. Data from 6 regional registries for 1999].
2001 Jan
Meropenem in neonatal severe infections due to multiresistant gram-negative bacteria.
2001 Jan
A prospective study of antibiotic use and associated infections in young children.
2001 Jan
[Prevalence of Moraxella catarrhalis colonization in asymptomatic carriers under 6 years of age].
2001 Jan-Feb
Charm Safe-Level beta-Lactam Test for amoxicillin, ampicillin, ceftiofur, cephapirin, and penicillin G in raw commingled milk.
2001 Jan-Feb
[A prospective study on erysipelas and infectious cellulitis: how are they dealt within hospital?].
2001 Mar
Peptic ulcer occurrence in follow-up of chronic gastritis in patients with treated and not eradicated CagA-positive Helicobacter pylori infection.
2001 Mar
Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998.
2001 Mar
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
2001 Mar
Osseintegration following treatment of peri-implantitis and replacement of implant components. An experimental study in the dog.
2001 Mar
Lacrimal gland ductal cyst abscess.
2001 Mar
Screening method for identification of beta-lactams in bovine urine by use of liquid chromatography and a microbial inhibition test.
2001 Mar
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
2001 Mar
Evaluation of the clinical microbiology profile of moxifloxacin.
2001 Mar 15
Tests for 2 x K contingency tables with clustered ordered categorical data.
2001 Mar 15
[Angina tonsillaris in children. Penicillin V can not be recommended here].
2001 Mar 22
Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group.
2001 Mar 31
Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group.
2001 Mar 31
Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome.
2001 May
Simultaneous determination of amoxycillin and clavulanic acid in pharmaceutical dosage forms by LC with amperometric detection.
2001 May
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Patents

Sample Use Guides

In adults, 750-1750 mg/day in divided doses every 8-12 hours. In Pediatric Patients > 3 Months of Age, 20-45 mg/kg/day in divided doses every 8-12 hours. Treatment of gonorrhea is 3 grams as a single oral dose. The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours. Dosing for H. pylori Infection: Triple therapy: 1 gram AMOXIL, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:55:49 UTC 2021
Edited
by admin
on Fri Jun 25 20:55:49 UTC 2021
Record UNII
804826J2HU
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
(2S,5R,6R)-6-((R)-(-)-2-AMINO-2-(P-HYDROXYPHENYL)ACETAMIDO)-3,3-DIMETHYL-7-OXO-4-THIA-1-AZABICYCL(3.2.0)HEPTANE-2-CARBOXYLIC ACID TRIHYDRATE
Common Name English
AMOXICILLIN TRIHYDRATE [MI]
Common Name English
AMOXICILLIN [ORANGE BOOK]
Common Name English
AMOXICILLIN TRIHYDRATE
EP   GREEN BOOK   MART.   MI   VANDF   WHO-DD   WHO-IP  
Common Name English
TRIMOX
Brand Name English
AMOXICILLIN [USP-RS]
Common Name English
AMOXICILLIN TRIHYDRATE [WHO-IP]
Common Name English
PROMOXIL
Common Name English
ATOKSILIN
Common Name English
AMOXICILLIN TRIHYDRATE [VANDF]
Common Name English
CLAVULOX COMPONENT AMOXICILLIN TRIHYDRATE
Common Name English
REMOXIL
Common Name English
LARGOPEN
Common Name English
TALICIA COMPONENT AMOXICILLIN
Brand Name English
AMOXICILLINUM TRIHYDRICUM [WHO-IP LATIN]
Common Name English
AMOXICILLIN TRIHYDRATE COMPONENT OF CLAVULOX
Common Name English
UTIMOX
Brand Name English
AMOXICILLIN [USP MONOGRAPH]
Common Name English
AMOXICILLIN COMPONENT OF TALICIA
Brand Name English
AMOXICILLIN (AS TRIHYDRATE)
Common Name English
AUGMENTIN COMPONENT AMOXICILLIN
Brand Name English
POLYMOX
Brand Name English
DEMOKSIL
Common Name English
DISPERMOX
Brand Name English
AMOXICILLIN [USAN]
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 6-((AMINO(4-HYDROXYPHENYL)ACETYL)AMINO)-3,3-DIMETHYL-7-OXO-, TRIHYDRATE(2S-(2.ALPHA.,5.ALPHA.,6.BETA.(S*)))-
Common Name English
PREVPAC COMPONENT AMOXICILLIN
Common Name English
AMOXICILLIN TRIHYDRATE [GREEN BOOK]
Common Name English
AMOXICILLIN TRIHYDRATE [MART.]
Common Name English
MOXATAG
Brand Name English
BRL-2333
Code English
MOKSILIN
Common Name English
AMOXICILLIN HYDRATE
JAN  
Common Name English
AMOXICILLIN HYDRATE [JAN]
Common Name English
DAMOXY
Common Name English
LAROTID
Brand Name English
TOPRAMOXIN
Common Name English
AMOXICILLIN TRIHYDRATE [EP MONOGRAPH]
Common Name English
AMOXICILLIN [USP]
Common Name English
AMOXICILLIN COMPONENT OF PREVPAC
Common Name English
AMOXIL
Brand Name English
AMOXYKE
Common Name English
AMOXICILLIN TRIHYDRATE [WHO-DD]
Common Name English
WYMOX
Brand Name English
AMOXICILLIN [VANDF]
Common Name English
BRL 2333
Code English
AMOXICILLIN COMPONENT OF AUGMENTIN
Brand Name English
Classification Tree Code System Code
WHO-ATC A02BD06
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 520.88
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ATC A02BD07
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QA02BD07
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.1 (AMO/CLA)
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ATC J01CR02
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QA02BD01
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
NCI_THESAURUS C1500
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 520.88E
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QA02BD04
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 520.88B
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ATC A02BD03
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 526.88
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QA02BD05
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QJ01CA04
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ATC A02BD10
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 520.88H
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ATC A02BD05
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ATC J01CA04
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QJ01CR02
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 520.88C
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ATC A02BD04
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
NDF-RT N0000175497
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ATC A02BD11
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 520.88F
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QG51AA03
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QA02BD03
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 520.88A
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
LIVERTOX 49
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 520.88G
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QA02BD06
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-VATC QJ51CR02
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 556.38
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 522.88
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
WHO-ATC A02BD01
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
CFR 21 CFR 520.88D
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
Code System Code Type Description
RXCUI
723
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
ALTERNATIVE
MESH
D000658
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
LACTMED
Amoxicillin and Clavulanic Acid
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
LACTMED
Amoxicillin
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
DRUG BANK
DB01060
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
EPA CompTox
61336-70-7
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
ChEMBL
CHEMBL1082
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
NCI_THESAURUS
C237
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
MERCK INDEX
M1844
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY Merck Index
WHO INTERNATIONAL PHARMACOPEIA
AMOXICILLIN
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Slightly soluble in water and methanol R; very slightly soluble in ethanol (~750 g/l) TS, ether R, and fatty oils; soluble in dilute acids and dilute solutions of alkali hydroxides. Category: Antibacterial drug. Storage: Amoxicillin trihydrate should be kept in a tightly closed container. Requirement: Amoxicillin trihydrate contains not less than 95.0% and not more than the equivalent of 102.0% of C16H19N3O5S, calculated with reference to the anhydrous substance.
USP_CATALOG
1031503
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY USP-RS
CAS
61336-70-7
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
FDA UNII
804826J2HU
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
EVMPD
SUB00504MIG
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
WIKIPEDIA
AMOXICILLIN
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
PUBCHEM
62883
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
RXCUI
133008
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
DRUG CENTRAL
192
Created by admin on Fri Jun 25 20:55:49 UTC 2021 , Edited by admin on Fri Jun 25 20:55:49 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
PARENT -> SALT/SOLVATE
TRANSPORTER -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC EXTENDED-RELEASE DOSE
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL EXTENDED-RELEASE DOSE
PHARMACOKINETIC